Form D · Biotechnology
Theriva Biologics, Inc.
Rockville, MD · CIK 0000894158
Offering snapshot reported Oct 24, 2025 · SEC filing
- Reported sold
- $13.1M Offering amount: $13.1M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 17, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 24, 2025 | Initial | $13,109,494 | No comparison | 10 | SEC filing |
| Aug 4, 2022 | Initial | $3,000,000 | No comparison | 1 | SEC filing |
| Mar 21, 2022 | Initial | $1,467,502 | No comparison | 4 | SEC filing |
| Sep 13, 2017 | Initial | $12,000,000 | No comparison | 1 | SEC filing |
| Nov 5, 2012 | Initial | $10,800,000 | No comparison | 22 | SEC filing |
| Oct 22, 2012 | Initial | $7,637,252 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $308K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-561937
Includes $4,369,831.20 in proceeds from exercise of existing registered warrants pursuant to Warrant Inducement Letter Agreement and $8,739,663 in total gross proceeds to be received from cash exercise of all new warrants issued in private placement.
A.G.P/Alliance Global Partners LP was paid by the Issuer a cash fee equal to 7.0% of the aggregate gross proceeds received upon exercise of the existing registered warrants and reimbursement of certain expenses.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| A.G.P./Alliance Global Partners | 000008361 |
Source: Form D, filed Oct 24, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| C. Evan Ballantyne | Executive |
| Steve Kanzer | Director |
| Jeffrey J. Kraws | Director |
| John Monahan | Director |
| Jeffrey Riley | Director, Executive |
| Steven A. Shallcross | Director, Executive |
| Joseph Sliman | Executive |
| Scott Tarriff | Director |
| Jeffrey A. Wolf | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
9605 Medical Center Drive Suite 270
Rockville, MD, 20850
Rockville, MD, 20850